Abstract
Small clinical studies have shown that oral treatment with the plant alkaloid berberine (BBR) reduces blood glucose levels similar to that of metformin and have promoted its use as a novel anti-diabetic therapy. However, in vitro studies have shown that high concentrations of BBR potently inhibit cell proliferation through inhibition of mitochondrial function. Cardiolipin (Ptd2Gro) is a key phospholipid required for regulating mitochondrial bioenergetic function. We examined if BBR inhibited oxygen consumption rate in H9c2 cardiac myocytes through alteration in Ptd2Gro metabolism. Treatment of H9c2 cells with BBR resulted in a rapid (within minutes) concentration-dependent decrease in the oxygen consumption rate (OCR) as determined using a Seahorse XF24 analyzer. Concentrations of BBR as low as 1 µM were effective in inhibiting OCR. In addition, all concentrations of BBR inhibited the fatty acid-mediated increase in OCR that was observed in untreated cells. Treatment of H9c2 cells with up to 25 µM BBR for 24 h markedly reduced [3H]thymidine incorporation into cells but did not alter the pool size of Ptd2Gro. In contrast, 12.5 µM BBR increased [1-14C]palmitate incorporation into Ptd2Gro and 12.5 µM and 25 µM BBR reduced [1-14C]oleate incorporation into Ptd2Gro. Protein kinase C delta (PKCδ) activation through its increased membrane association is known to alter Ptd2Gro distribution within mitochondria. BBR treatment resulted in a decrease in membrane-associated PKCδ and attenuated the palmitate-mediated increase in PKCδ membrane-association. Thus, BBR treatment of H9c2 cardiac myocytes inhibits cellular OCR independent of alteration in Ptd2Gro levels.
Abbreviations
- BBR:
-
Berberine
- BSA:
-
Bovine serum albumin
- Ptd2Gro:
-
Cardiolipin
- PKCδ:
-
Protein kinase C delta
- DAG:
-
Diacyglycerol
References
Chang W, Chen L, Hatch GM (2015) Berberine as a therapy for type 2 diabetes and its complications: from mechanism of action to clinical studies. Biochem Cell Biol 93(5):479–486
Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, Perkins EL, Serafim TL, Sardão VA, Santos MS, Moreno AJ, Holy J, Oliveira PJ (2007) Mitochondrially targeted effects of berberine [natural yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Expt Ther. 323(2):636–649
Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57(5):1414–1418
Yan XJ, Yu X, Wang XP, Jiang JF, Yuan ZY, Lu X, Lei F, Xing DM (2017) Mitochondria play an important role in the cell proliferation suppressing activity of berberine. Sci Rep. 9(7):41712
Horvath SE, Daum G (2013) Lipids of mitochondria. Prog Lipid Res 52(4):590–614
Mejia EM, Hatch GM (2016) Mitochondrial phospholipids: role in mitochondrial function. J Bioenerg Biomembr 48(2):99–112
Chang W, Chen L, Hatch GM (2016) Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes. Biochim Biophys Acta 1861(4):352–362
Hatch G, McClarty G (1996) Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5′-triphosphate. J Biol Chem 271(42):25810–25816
Cole LK, Mejia EM, Vandel M, Sparagna GC, Claypool SM, Dyck-Chan L, Klein J, Hatch GM (2016) Impaired cardiolipin biosynthesis prevents hepatic steatosis and diet-induced obesity. Diabetes 65(11):3289–3300
Hauff K, Linda D, Hatch GM (2009) Mechanism of the elevation in cardiolipin during HeLa cell entry into the S-phase of the human cell cycle. Biochem J 417(2):573–582
Nguyen T, Ogbi M, Johnson JA (2008) Delta protein kinase C interacts with the d subunit of the F1F0 ATPase in neonatal cardiac myocytes exposed to hypoxia or phorbol ester. Implications for F1F0 ATPase regulation. J Biol Chem 283(44):29831–29840
Xu M, Xiao Y, Yin J, Hou W, Yu X, Li Shen, Liu F, Li Wei, Jia W (2014) Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS One 9(7):e103702
Chen Y, Li Y, Wang Y, Wen Y, Sun C (2009) Berberine improves free-fatty-acid–induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor γ and fatty acid transferase expressions. Metabol Clin Expt 58:1694–1702
Ckless K, Schlottfeldt JL, Pasqual M, Moyna P, Henriques JA, Wajner M (1995) Inhibition of in vitro lymphocyte transformation by the isoquinoline alkaloid berberine. J Pharm Pharmacol 47(12A):1029–1031
Lokhmatikov AV, Voskoboynikova NE, Cherepanov DA, Sumbatyan NV, Korshunova GA, Skulachev MV, Steinhoff HJ, Skulachev VP, Mulkidjanian AY (2014) Prevention of peroxidation of cardiolipin liposomes by quinol-based antioxidants. Biochem (Moscow) 79(10):1081–1100
He Y, Liu J, Grossman D, Durrant D, Sweatman T, Lothstein L, Epand RF, Epand RM, Lee RM (2007) Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem 101(5):1210–1221
Van Q, Liu J, Lu B, Feingold KR, Shi Y, Lee RM, Hatch GM (2007) Phospholipid scramblase-3 regulates cardiolipin de novo biosynthesis and its resynthesis in growing HeLa cells. Biochem J 401:103–109
Byun HO, Jung HJ, Kim MJ, Yoon G (2014) PKCδ phosphorylation is an upstream event of GSK3 inactivation-mediated ROS generation in TGF-β1-induced senescence. Free Radic Res 48:1100–1108
Spinozz S, Colliva C, Camborata C, Roberti M, Ianni C, Neri F, Calvarese C, Lisotti A, Mazzella G, Roda A (2014) Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod 77:766–772
Zhaojie M, Ming Z, Shengnan W, Xiaojia B, Hatch GM, Jingkai G, Li C (2014) Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int J Pharm 467(1–2):50–59
Acknowledgements
Support was received by grants from the Heart and Stroke Foundation of Canada and National Sciences and Engineering Research Council (to G.M.H.), National Science Fund for Excellent Young Scholars (81622005) (to W.C.) and the National Natural Science Foundation of China (81503122) (to L.C.). G.M.H. is a Canada Research Chair in Molecular Cardiolipin Metabolism.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Chang, W., Zhang, M., Chen, L. et al. Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells. Lipids 52, 961–967 (2017). https://doi.org/10.1007/s11745-017-4300-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11745-017-4300-z